Bluejay Diagnostics (NASDAQ:BJDX) Releases Earnings Results, Beats Expectations By $3,518.28 EPS

Bluejay Diagnostics (NASDAQ:BJDX) announced its earnings results on Thursday. The company reported ($1.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.28, FiscalAI reports.

Bluejay Diagnostics Price Performance

BJDX stock traded down $0.19 during midday trading on Thursday, hitting $2.61. The stock had a trading volume of 17,710 shares, compared to its average volume of 538,357. The business has a 50-day moving average of $3.10 and a two-hundred day moving average of $7.05. The firm has a market cap of $2.92 million, a price-to-earnings ratio of -0.09 and a beta of 0.92. Bluejay Diagnostics has a 52-week low of $1.84 and a 52-week high of $28.00.

Wall Street Analyst Weigh In

BJDX has been the subject of a number of research reports. Wall Street Zen downgraded shares of Bluejay Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, September 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Monday, September 21st. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Bluejay Diagnostics has a consensus rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc. is a medical technology company focused on developing rapid, point-of-care diagnostic testing solutions. The company’s technology is designed to provide healthcare professionals with timely information from blood samples, supporting clinical decision-making in settings where conventional laboratory testing may take longer. Its primary product is the Symphony system, a diagnostic platform consisting of an analyzer and disposable test cartridges. The platform is intended to measure biomarkers in whole blood and is being developed for applications including the assessment and management of serious medical conditions such as sepsis and other critical-care situations.